23andMe gets to IPO immediately without having to go through a lot of the regulatory work that would normally happen in a direct listing because the SPAC acquiring them is already public. This means they can get a good percentage of the normal cash infusion with half the hassle.

Those creating the SPAC get a discounted price on the stock they eventually take public, but for the bill via increased risk they might not get a good company.